On December 16, Regeneron said its cocktail drug had diminished potency against Omicron. But 13 days later, Cipla held a webinar to promote its use in India.
The recent emergence of the highly-transmissible B.1.1.529 Omicron variant is especially concerning because of the number of mutations - more than 30 in the spike protein.